Abstract
背景Median survival for cystic fibrosis (CF) patients in Europe is unknown and is likely to be influenced by socioeconomic factors. Using the European CF Society Patient Registry (ECFSPR), median survival estimates were obtained for CF patients across Europe and the impact of socioeconomic status on survival was examined.
Methods包括2010年至2014年之间的CF受试者,在2010年至2014年之间的ECFSPR中。使用Kaplan – Meier方法估算存活曲线。使用对数秩检验评估生存曲线的差异。COX回归用于估计社会经济因素与特定年龄危害的死亡危害之间的关联,并调整性别,诊断年龄,CF跨膜电导调节器(CFTR) genotype and transplant status.
ResultsThe final analysis included 13 countries with 31 987 subjects (135 833 person-years of follow-up) and 1435 deaths. Median survival age for these patients in the ECFSPR was 51.7 (95% CI 50.0–53.4) years. After adjusting for potential confounders age at diagnosis, sex,CFTRgenotype and transplant status, there remained strong evidence of an association between socioeconomic factors and mortality (p<0.001). Countries in the highest third of healthcare spending had a 46% lower hazard of mortality (HR 0.54, 95% CI 0.45–0.64) than countries in the lowest third of healthcare spending.
结论Median survival for patients with CF in Europe is comparable to that reported in other jurisdictions and differs by socioeconomic factors.
Abstract
欧洲CF患者的中位生存期与其他司法管辖区报告相似,并且根据社会经济状况而有所不同,其措施与改善生存有关的较高医疗保健支出的措施。https://bit.ly/3jyf37q
Footnotes
This article has supplementary material available fromwww.qdcxjkg.com
作者贡献:E.F. McKone可以完全访问所有数据和决定发布的最终责任。所有作者都参与了数据收集或研究设计以及手稿准备和审查。
Conflict of interest: E.F. McKone reports grants and personal fees from Vertex Pharmaceuticals, personal fees from Novartis, nonfinancial support from A Menarini, and grants from Gilead, outside the submitted work.
利益冲突:C。Ariti无话可说。
Conflict of interest: A. Jackson has nothing to disclose.
利益冲突:A。Zolin没有什么可披露的。
Conflict of interest: S.B. Carr reports nonfinancial support and other from Chiesi Pharmaceuticals (Advisory Board fee), nonfinancial support and other from Vertex Pharmaceuticals (Advisory Board, lecture fee, travel, Steering Committee), other from Zambon Pharmaceuticals (Advisory Board fee), other from Insmed (Advisory Board fee), outside the submitted work.
利益冲突:A。Orenti没有什么可披露的。
利益冲突:J.G。范·伦斯没有什么可披露的。
利益冲突:l . Lemonnier无关disclose.
利益冲突:M。Macek Jr没有什么可披露的。
利益冲突:R.H. Keogh无话可说。
Conflict of interest: L. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals.
支持声明:本研究没有向ECFSPR提供外部资金。统计分析是通过ECFSPR授予伦敦卫生学院和热带医学学院的赠款来资助的。本文的资金信息已存入CrossRef资助人注册表。
- ReceivedJune 12, 2020.
- 公认February 12, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contactpermissions{at}ersnet.org